A health tech start up, Quin, has launched an equity crowdfunding campaign to for its diabetes management app.
The AI driven app, for diabetes management uses algorithmic insights to help people decide when and how much insulin to take.
The campaign, which aims to raise £600k, started this month through the Seedrs crowdfunding platform, and the company aims to use the funds for further app development and a product launch.
Cyndi Williams, CEO and Co-Founder “Today marks a huge step as Quin takes a seat in the tech space with an app that could transform the lives of so many people who are living with insulin-treated diabetes. With the funds we hope to raise, we want to help people take back control and find their personal balance by reducing the self-care decision-making load.We are therefore opening our doors to those who want to invest in our future growth and invite everyone to become a partner in this noble initiative.”
The company has raised £2 million to date and has recruited hundreds of beta testers, and launched its ML research partnership with the University of Bristol. The company has also filed for two patents.
The app aims to humanise diabetes technology by utilising the knowledge and experience of people who take insulin to create a more personalised insulin treatment regime. It uses a machine learning algorithm trained on data from existing diabetes-management devices, sensors and phones to help people decide how much insulin is right for them, and when best to take it.
Professor Jeremy Turner, endocrinologist, Norfolk and Norwich University Hospitals NHS Foundation Trust, and Quin’s medical advisor “The use of heuristics to gather large amounts of real-world biological data from thousands of subjects allows researchers to look at the behaviour of blood glucose and defective insulin signalling in a way that’s never been possible before.”
